Literature DB >> 19707508

Hepatic metastases of gastric adenocarcinoma showing metabolic remission on FDG-PET despite an increase in size on CT.

So Young Yoon1, Sung-Yong Kim, Yo-Han Cho, Hyun Woo Chung, Young So, Hong M Lee.   

Abstract

We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (1-6). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.

Entities:  

Keywords:  Hepatic metastasis; Metabolic remission; Positron-emission tomography; Stomach neoplasms

Year:  2009        PMID： 19707508      PMCID： PMC2731211          DOI： 10.4143/crt.2009.41.2.100

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN： 1598-2998            Impact factor:   4.679


  8 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.

Authors:  Ghassan K Abou-Alfa; Lawrence Schwartz; Sergio Ricci; Dino Amadori; Armando Santoro; Arie Figer; Jacques De Greve; Jean-Yves Douillard; Chetan Lathia; Brian Schwartz; Ian Taylor; Marius Moscovici; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

Review 3.  Targeted therapy for metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2006-12-10       Impact factor: 44.544

4.  We should desist using RECIST, at least in GIST.

Authors:  Robert S Benjamin; Haesun Choi; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Chuslip Charnsangavej
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

5.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

Authors:  Haesun Choi; Chuslip Charnsangavej; Silvana C Faria; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Robert S Benjamin
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

6.  The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.

Authors:  G W Goerres; R Stupp; G Barghouth; T F Hany; B Pestalozzi; E Dizendorf; P Schnyder; F Luthi; G K von Schulthess; S Leyvraz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-09-04       Impact factor: 9.236

7.  Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.

Authors:  Gerald Antoch; Jörg Kanja; Sebastian Bauer; Hilmar Kuehl; Katrin Renzing-Koehler; Jochen Schuette; Andreas Bockisch; Jörg F Debatin; Lutz S Freudenberg
Journal:  J Nucl Med       Date:  2004-03       Impact factor: 10.057

8.  18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

Authors:  S Stroobants; J Goeminne; M Seegers; S Dimitrijevic; P Dupont; J Nuyts; M Martens; B van den Borne; P Cole; R Sciot; H Dumez; S Silberman; L Mortelmans; A van Oosterom
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162
  8 in total
  3 in total

Review 1.  Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.

Authors:  Elizabeth C Smyth; Manish A Shah
Journal:  World J Gastroenterol       Date:  2011-12-14       Impact factor: 5.742

2.  Phase II study of sunitinib as second-line treatment for advanced gastric cancer.

Authors:  Yung-Jue Bang; Yoon-Koo Kang; Won K Kang; Narikazu Boku; Hyun C Chung; Jen-Shi Chen; Toshihiko Doi; Yan Sun; Lin Shen; Shukui Qin; Wai-Tong Ng; Jennifer M Tursi; Maria J Lechuga; Dongrui Ray Lu; Ana Ruiz-Garcia; Alberto Sobrero
Journal:  Invest New Drugs       Date:  2010-05-12       Impact factor: 3.850

3.  A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis.

Authors:  Ch'angbum Rim; Jung-Ae Lee; Soojung Gong; Dong Wook Kang; Heebum Yang; Hyun Young Han; Nae Yu Kim
Journal:  J Gastric Cancer       Date:  2016-06-24       Impact factor: 3.720
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.